Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lineage Cell Therapeutics, Inc.

NYSE: LCTX · Life Sciences · 3 alerts · CIK 876343

Share price
$0.7951Close, Nov 16
Market cap
$201M
Shares outstanding
252.95MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lineage Cell Therapeutics, Inc. filings on SEC EDGAR ↗

8:45 AM ET Form 4
Insider Buying

Lineage Cell Therapeutics President and CEO Brian M. Culley Buys $37.1K of Stock

Brian M. Culley, President and CEO, bought 40,500 shares of Lineage Cell Therapeutics, Inc. at $0.916 a share, worth $37.1K in total on Nov 16, 2026. Shares held after the trade: 296,016 (+15.9%).

Value
$37.1K
Shares
40,500
Price
$0.9160
Role
President and CEO
Holding change
+15.9%
Trade date
Nov 16, 2026
4:21 PM ET 10-Q
Financial Results

Lineage Cell Therapeutics Q3 2026 Results: Turns Profitable, Net Income $4.23M

For the nine months ended September 30, 2026, Lineage Cell Therapeutics reported total revenues of $4.2 million, a decrease from $7.9 million in the prior year, primarily due to lower collaboration revenues. The company significantly reduced its net loss compared to 2025, aided by a substantial $31.2 million non-cash gain from the change in fair value of warrant liabilities.

Key figure
Net income $4.23M
4:11 PM ET 8-K
M&A Deal

Lineage Cell Therapeutics Signs $2.4M M&A Deal with NeuroAirmid Therapeutics, Inc.

Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, Inc., adding a clinical-stage neural cell therapy program (HUNT1) for Huntington’s Disease to its pipeline. The deal involved a $2.4 million upfront cash payment and the assumption of a co-funding obligation for an ongoing Phase 1b/2a clinical study supported by CIRM.

Value
$2.4M
Counterparty
NeuroAirmid Therapeutics, Inc.

“Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline. HUNT1 is a pluripotent stem cell derived, clinical-stage neural cell therapy program, with the potential to validate a new cell-based treatment modality for Huntington’s Disease.”

Brian M. Culley, Lineage CEO

“This transaction reflects the disciplined approach to capital allocation and strategic fit that we believe our investors have come to expect from Lineage. HUNT1 was created on the same proprietary cell line that Lineage uses and is compatible with its AlloSCOPE “5D” technology, providing us with a head start on our planned contributions.”

Brian M. Culley, Lineage CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.